The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future
Copyright © 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved..
At the end of December 2019, a novel coronavirus, 2019-nCoV, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China, which has posed great threats to public health and attracted enormous attention around the world. To date, there are no clinically approved vaccines or antiviral drugs available for these human coronavirus infections. Intensive research on the novel emerging human infectious coronaviruses is urgently needed to elucidate their route of transmission and pathogenic mechanisms, and to identify potential drug targets, which would promote the development of effective preventive and therapeutic countermeasures. Herein, we describe the epidemic and etiological characteristics of 2019-nCoV, discuss its essential biological features, including tropism and receptor usage, summarize approaches for disease prevention and treatment, and speculate on the transmission route of 2019-nCoV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Microbes and infection - 22(2020), 2 vom: 15. März, Seite 80-85 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Jin-Yan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV |
|---|
| Anmerkungen: |
Date Completed 18.03.2020 Date Revised 13.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.micinf.2020.02.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30680199X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30680199X | ||
| 003 | DE-627 | ||
| 005 | 20231225124154.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.micinf.2020.02.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1022.xml |
| 035 | |a (DE-627)NLM30680199X | ||
| 035 | |a (NLM)32087334 | ||
| 035 | |a (PII)S1286-4579(20)30030-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Jin-Yan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2020 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a At the end of December 2019, a novel coronavirus, 2019-nCoV, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China, which has posed great threats to public health and attracted enormous attention around the world. To date, there are no clinically approved vaccines or antiviral drugs available for these human coronavirus infections. Intensive research on the novel emerging human infectious coronaviruses is urgently needed to elucidate their route of transmission and pathogenic mechanisms, and to identify potential drug targets, which would promote the development of effective preventive and therapeutic countermeasures. Herein, we describe the epidemic and etiological characteristics of 2019-nCoV, discuss its essential biological features, including tropism and receptor usage, summarize approaches for disease prevention and treatment, and speculate on the transmission route of 2019-nCoV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 2019-nCoV | |
| 650 | 4 | |a ACE2 | |
| 650 | 4 | |a Bat | |
| 650 | 4 | |a Pneumonia | |
| 650 | 4 | |a SARS-CoV | |
| 650 | 4 | |a Spike | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Receptors, Virus |2 NLM | |
| 700 | 1 | |a You, Zhi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qiong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Zhi-Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Xing-Yi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Microbes and infection |d 1999 |g 22(2020), 2 vom: 15. März, Seite 80-85 |w (DE-627)NLM105022780 |x 1769-714X |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g number:2 |g day:15 |g month:03 |g pages:80-85 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.micinf.2020.02.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |e 2 |b 15 |c 03 |h 80-85 | ||